Pasithea Therapeutics Corp. (KTTA)

Business: Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders.

IPO Date: 15-Sep-2021

Exec. Chairman & Co-Founder: Prof. Lawrence Steinman BA, M.D.

CEO & Director: Dr. Tiago Reis Marques

Listing: NASDAQ: KTTA

Country: United States

Headquarters: Miami Beach, FL

Website: https://www.pasithea.com

Market cap: $22.56 Mln

Revenue (TTM): $0.03 Mln

Earnings (TTM): $-3.20 Mln

Cash: $50.32 Mln

Total Debt: $0.00 Mln

Insider's Holding: 10.48%

Liquidity: Low

52 Week range: $0.81 - 8.50

Shares outstanding: 23,287,800